Advanced Application of Polymer-Based Biomaterials

A special issue of Medicina (ISSN 1648-9144).

Deadline for manuscript submissions: closed (31 March 2021) | Viewed by 1958

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomaterials and Healthcare, Division of Life Science and Bioprocesses, Fraunhofer Institute for Applied Polymer Research (IAP), Geiselbergstraße 69, 14476 Potsdam-Golm, Germany
Interests: microbiology; infectious diseases; new therapies for infectious diseasis; research on protective methods against infectins; complementary medicine; biomaterials research and interaction with microorganisms; development of Cosmeceutical; evaluation of potential active ingredients screening; in vitro testing

Special Issue Information

Dear Colleagues,

Polymers play a significant role in our lives. Every organism (including viruses) is built from natural polymers (also known as biopolymers) such as the carbohydrates and derivatives, proteins, DNA and RNA, and much more. Natural polymers can be modified to adopt special features, making them suitable for an almost unlimited number of applications. In addition to the natural and natural-based polymers, a huge class of fully synthetic polymers has also been developed. Native, modified, native-based and synthetic polymers alike find very attractive applications in medical devices, especially in biomaterials. Biomaterials are natural and/or synthetic materials that find their final application in direct contact and therefore interaction with living tissue for therapeutic and/or diagnostic purposes. Many modern drug delivery systems are based on the use of polymers in order to improve the selectivity to the target tissue or to improve the bioavailability of certain drugs to overcome issues associated with small molecule drug therapies.

Due to the current worldwide COVID-19 pandemic and associated diseases, special interest is also given to therapeutic approaches which are based on polymeric structures (e.g., soluble ACE-2 receptor, vaccination, polymeric nano-carriers, etc.)

Contributions from all disciplines with a focus on the research and development of medical therapeutic and diagnostic systems for application in living systems are greatly welcome.

Reviews or original articles dealing with the medical aspects associated with biomaterials in experimental models and humans, as well as articles providing an up-to-date overview of the diagnosis, management, and treatment of diseases are welcome. In addition, we invite you to submit articles reporting on evidence and expectations from innovative polymer-based therapeutics, as well as articles contributing to the uses of polymers with strong applications in the healthcare sector.

Dr. Joachim Storsberg
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Polymer based biomaterials
  • Medical implants, artificial organs
  • Polymer based drug delivery systems
  • Polymer based diagnostic systems
  • Antibodies (natural) and synthetic for the treatment of diseases
  • Viruses and bacteria
  • PCR techniques
  • ELISA
  • Protection systems such as respiratory masks
  • Live supporting systems, emergency systems

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 2486 KiB  
Article
Evaluation of Antinociceptive Effects of Chitosan-Coated Liposomes Entrapping the Selective Kappa Opioid Receptor Agonist U50,488 in Mice
by Liliana Mititelu Tartau, Maria Bogdan, Beatrice Rozalina Buca, Ana Maria Pauna, Cosmin Gabriel Tartau, Lorena Anda Dijmarescu and Eliza Gratiela Popa
Medicina 2021, 57(2), 138; https://doi.org/10.3390/medicina57020138 - 4 Feb 2021
Cited by 2 | Viewed by 1521
Abstract
Background and Objectives: The selective kappa opioid receptor agonist U50,488 was reported to have analgesic, cough suppressant, diuretic and other beneficial properties. The aim of our study was to analyze the effects of some original chitosan-coated liposomes entrapping U50,488 in somatic and [...] Read more.
Background and Objectives: The selective kappa opioid receptor agonist U50,488 was reported to have analgesic, cough suppressant, diuretic and other beneficial properties. The aim of our study was to analyze the effects of some original chitosan-coated liposomes entrapping U50,488 in somatic and visceral nociceptive sensitivity in mice. Materials and Methods: The influence on the somatic pain was assessed using a tail flick test by counting the tail reactivity to thermal noxious stimulation. The nociceptive visceral estimation was performed using the writhing test in order to evaluate the behavioral manifestations occurring as a reaction to the chemical noxious peritoneal irritation with 0.6% acetic acid (10 mL/kbw). The animals were treated orally, at the same time, with a single dose of: distilled water 0.1 mL/10 gbw; 50 mg/kbw U50,488; 50 mg/kbw U50,488 entrapped in chitosan-coated liposomes, according to the group they were randomly assigned. Results: The use of chitosan-coated liposomesas carriers for U50,488 induced antinociceptive effects that began to manifest after 2 h, andwere prolonged but with a lower intensity than those caused by the free selective kappa opioid in both tests. Conclusion: In this experimental model, the oral administration of nanovesicles containing the selective kappa opioid agonist U50,488 determined a prolonged analgesic outcome in the tail flick test, as well as in the writhing test. Full article
(This article belongs to the Special Issue Advanced Application of Polymer-Based Biomaterials)
Show Figures

Figure 1

Back to TopTop